mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021482 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Paula Cilleros-Holgado und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), 41013 Sevilla, Spain. Hauptthemen laut MEDLINE: Mitochondrial Diseases. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Regional Government of Andalusia.
Abstract (Originalsprache)
Mitochondrial dysfunction is a key pathological event in many diseases. Its role in energy production, calcium homeostasis, apoptosis regulation, and reactive oxygen species (ROS) balance render mitochondria essential for cell survival and fitness. However, there are no effective treatments for most primary and secondary mitochondrial diseases to this day. Therefore, new therapeutic approaches, such as the modulation of the mitochondrial unfolded protein response (mtUPR), are being explored. mtUPRs englobe several compensatory processes related to proteostasis and antioxidant system mechanisms. mtUPR activation, through an overcompensation for mild intracellular stress, promotes cell homeostasis and improves lifespan and disease alterations in biological models of mitochondrial dysfunction in age-related diseases, cardiopathies, metabolic disorders, and primary mitochondrial diseases. Although mtUPR activation is a promising therapeutic option for many pathological conditions, its activation could promote tumor progression in cancer patients, and its overactivation could lead to non-desired side effects, such as the increased heteroplasmy of mitochondrial DNA mutations. In this review, we present the most recent data about mtUPR modulation as a therapeutic approach, its role in diseases, and its potential negative consequences in specific pathological situations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), 41013 Sevilla, Spain.
ORCID-Profile: Jose Antonio Sánchez-Alcázar
Förderung
- Instituto de Salud Carlos III
- Regional Government of Andalusia
Zitieren
APA
Cilleros-Holgado, P., Gómez-Fernández, D., Piñero-Pérez, R., Reche-López, D., Álvarez-Córdoba, M., Munuera-Cabeza, M., Talaverón-Rey, M., Povea-Cabello, S., Suárez-Carrillo, A., Romero-González, A., Suárez-Rivero, J. M., Romero-Domínguez, J. M., & Sánchez-Alcázar, J. A. (2023). mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021482
Vancouver
Cilleros-Holgado P, Gómez-Fernández D, Piñero-Pérez R, Reche-López D, Álvarez-Córdoba M, Munuera-Cabeza M, et al. mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021482
BibTeX
@article{CillerosHolgado2023,
author = {Cilleros-Holgado, Paula and Gómez-Fernández, David and Piñero-Pérez, Rocío and Reche-López, Diana and Álvarez-Córdoba, Mónica and Munuera-Cabeza, Manuel and Talaverón-Rey, Marta and Povea-Cabello, Suleva and Suárez-Carrillo, Alejandra and Romero-González, Ana and Suárez-Rivero, Juan Miguel and Romero-Domínguez, Jose Manuel and Sánchez-Alcázar, Jose Antonio},
title = {mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021482}
}
EUVIMED